MITCHELL LANGE: Open Payments
NPI 1992432249 · VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$478 in 23 payments from 13 companies in 2025. Trend: 2023 $305 · 2024 $400 · 2025 $478
Food & beverage: $478
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $85 |
| Lilly USA, LLC | 4 | $69 |
| Gilead Sciences, Inc. | 2 | $61 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Dexcom, Inc. | 2 | $37 |
| Boston Scientific Corporation | 1 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Cranial Technologies, Inc | 1 | $21 |
| Exact Sciences Corporation | 1 | $20 |
Products named: Rybelsus, COBENFY, Dexcom G6 Transmitter, WaveWriter Alpha Prime 16, MOUNJARO, JARDIANCE, Wegovy, SHINGRIX.
Industry payments across CA — which companies pay providers there.
